UBX Unity Biotechnology Inc
Price (delayed)
$1.06
Market cap
$17.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.54
Enterprise value
$30.01M
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells
Highlights
UBX's debt is down by 16% year-on-year and by 4.8% since the previous quarter
The EPS is up by 43% year-on-year but it is down by 21% since the previous quarter
UBX's net income is up by 35% YoY but it is down by 19% from the previous quarter
UBX's equity has dropped by 77% year-on-year and by 54% since the previous quarter
The quick ratio has plunged by 54% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of UBX
Market
Valuations
Earnings
Shares outstanding
16.87M
Market cap
$17.88M
Enterprise value
$30.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.17M
Net income
-$25.99M
EBIT
-$25.99M
EBITDA
-$25.12M
Free cash flow
-$20.84M
Per share
Balance sheet
Liquidity
EPS
-$1.54
EPS diluted
-$1.54
Free cash flow per share
-$1.24
Book value per share
$0.39
Revenue per share
$0
TBVPS
$2.24
Total assets
$37.66M
Total liabilities
$31.17M
Debt
$19.71M
Equity
$6.49M
Working capital
$15.01M
Debt to equity
3.03
Current ratio
2.62
Quick ratio
2.51
Net debt/EBITDA
-0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.7%
Return on equity
-161.5%
Return on invested capital
-48.2%
Return on capital employed
-91.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UBX stock price
How has the Unity Biotechnology stock price performed over time
Intraday
10.41%
1 week
-11.67%
1 month
-38.01%
1 year
-34.16%
YTD
8.56%
QTD
1.92%
Financial performance
How have Unity Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.17M
Net income
-$25.99M
Gross margin
N/A
Net margin
N/A
UBX's net income is up by 35% YoY but it is down by 19% from the previous quarter
UBX's operating income is up by 30% year-on-year but it is down by 8% since the previous quarter
Growth
What is Unity Biotechnology's growth rate over time
Valuation
What is Unity Biotechnology stock price valuation
P/E
N/A
P/B
2.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 43% year-on-year but it is down by 21% since the previous quarter
UBX's equity has dropped by 77% year-on-year and by 54% since the previous quarter
The P/B is 56% more than the last 4 quarters average of 1.6 and 38% more than the 5-year quarterly average of 1.8
Efficiency
How efficient is Unity Biotechnology business performance
UBX's return on equity has dropped by 75% year-on-year and by 59% since the previous quarter
UBX's ROA is down by 35% since the previous quarter and by 16% year-on-year
UBX's ROIC is down by 30% since the previous quarter and by 15% year-on-year
Dividends
What is UBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UBX.
Financial health
How did Unity Biotechnology financials performed over time
UBX's total assets is 21% greater than its total liabilities
The current ratio has shrunk by 56% YoY and by 24% QoQ
The quick ratio has plunged by 54% YoY and by 24% from the previous quarter
The company's debt to equity has surged by 108% QoQ
UBX's equity has dropped by 77% year-on-year and by 54% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.